Getein Biotech, Inc (SHA:603387)

China flag China · Delayed Price · Currency is CNY
8.75
0.00 (0.00%)
At close: Jan 23, 2026
11.04%
Market Cap4.44B
Revenue (ttm)1.04B
Net Income (ttm)208.76M
Shares Out507.15M
EPS (ttm)0.41
PE Ratio21.32
Forward PEn/a
Dividend0.18 (2.06%)
Ex-Dividend DateSep 15, 2025
Volume6,831,397
Average Volume7,822,381
Open8.78
Previous Close8.75
Day's Range8.70 - 8.84
52-Week Range7.31 - 9.04
Beta0.25
RSI62.63
Earnings DateApr 30, 2026

About Getein Biotech

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical immunity, and other fields, such as such as myocardium, inflammation, renal function, thyroid function, hormones, glucose metabolism, tumor, coagulatio... [Read more]

Sector Healthcare
Founded 2002
Employees 1,947
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603387
Full Company Profile

Financial Performance

In 2024, Getein Biotech's revenue was 1.16 billion, a decrease of -14.93% compared to the previous year's 1.37 billion. Earnings were 223.64 million, a decrease of -20.06%.

Financial Statements